Indication
Thrombotic Microangiopathy
5 clinical trials
5 products
Clinical trial
Multicentre Study of Nomacopan (rVA576) in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic MicroangiopathyStatus: Recruiting, Estimated PCD: 2025-06-01
Product
NomacopanProduct
HMPL-523Clinical trial
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic MicroangiopathyStatus: Recruiting, Estimated PCD: 2025-12-01
Product
NarsoplimabClinical trial
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy in Patients With High-Risk Neuroblastoma Receiving Tandem TransplantsStatus: Not yet recruiting, Estimated PCD: 2027-03-31
Product
DefibrotideClinical trial
Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) RecipientsStatus: Completed, Estimated PCD: 2022-04-04
Product
Eculizumab